摘要
目的:探讨孟鲁司特钠联合信必可都保治疗咳嗽变异性哮喘(CVA)的临床疗效。方法:抽取安阳市第六人民医院于2017年9月至2019年9月收治的CVA患者60例,依据随机数字表法将其分为观察组(30例)与对照组(30例)。对照组患者给予信必可都保治疗,观察组在对照组基础上结合孟鲁司特钠治疗。两组疗程均为12周。比较治疗后两组疗效,治疗前后咳嗽症状评分、肺功能、细胞炎症介质和免疫功能变化及不良反应发生情况。结果:观察组总有效率(93.33%,28/30)高于对照组(70.00%,21/30),差异有统计学意义(P<0.05)。观察组治疗后日间咳嗽和夜间咳嗽评分低于对照组(t=8.180、10.113,P<0.05)。观察组治疗后第1秒用力呼气量(FEV1)、用力肺活量(FVC)和最大呼气流量(PEF)高于对照组(t=5.427、6.021、7.688,P<0.05)。观察组治疗后血清肿瘤坏死因子-α(TNF-α)、血管细胞黏附分子-1(VCAM-1)和白细胞介素-6(IL-6)水平低于对照组(t=9.621、8.459、13.226,P<0.05)。两组均未见明显不良反应,且肝功能、肾功能、血常规、尿常规未见异常。结论:孟鲁司特钠联合信必可都保治疗CVA患者疗效明显,可改善患者肺功能,减轻炎症反应。
Objective To investigate the therapeutic effect of montelukast sodium combined with symbicort turbuhaler in the treatment of cough variant asthma.Methods The 60 patients with cough variant asthma in Anyang Sixth People’s Hospital from September 2017 to September 2019 were selected,and they were divided into observation group(30 cases)and control group(30 cases)according to the random number table method.The patients in the control group were treated with symbicort turbuhaler,while the patients in the observation group were treated with montelukast sodium on the basis of the control group.The course of treatment in the two groups was 12 weeks.The efficacy of two groups after treatment,scores of cough symptoms,pulmonary function,changes of cellular inflammatory mediators and immune function symbicort turbuhaler,and adverse reactions were compared between the two groups.Results The total efficienly in the observation group(93.33%,28/30)was higher than that in the control group(70.00%),the difference was statistically significant(P<0.05).The scores of daytime cough and night cough in the observation group were lower than those in the control group(t=8.180,10.113,P<0.05).Forced expiratory volume in the first second(FEV1),forced vital capacity(FVC)and maximum expiratory flow(PEF)in the observation group were higher than those in the control group(t=5.427,6.021,7.688,P<0.05).The levels of tumor necrosis factor-α(TNF-α),vascular cell adhesion molecule-1(VCAM-1)and interleukin-6(IL-6)in the observation group were lower than those in the control group(t=9.621,8.459,13.226,P<0.05).No obvious adverse reactions were found in both groups,and no abnormality was found in liver and kidney function,blood routine and urine routine.Conclusions Montelukast sodium combined with symbicort turbuhaler is effective in the treatment of cough variant asthma.It can improve lung function,reduce inflammation.
作者
罗霄云
申琳
张文娜
Luo Xiaoyun;Shen Lin;Zhang Wenna(Department of Anyang Sixth People’s Hospital,Respiratory Medicine,Anyang 455000,China)
出处
《中国实用医刊》
2020年第14期118-121,共4页
Chinese Journal of Practical Medicine
